

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Saturday, December 9, 2023</b>		
1385 STAG2 loss Induces HSC Programs By Modulating Accessibility of AP-1 Bound Enhancers	Amy Wang	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1393 Functional Dissection of Cellular Programs to Uncover Novel Gene Dependencies in AML	Jana M. Ellegast, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1456 Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen	Hari S. Raman, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1478 What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study	Shai Shimony, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1509 A Phase I Study of Venetoclax in Combination with Inotuzumab Ozogamicin for Relapsed or Refractory ALL in Adults	Marlise R. Luskin, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1549 Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome	Eric S. Winer, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1596 Tracking of Leukemia and Immune Single Cell Phenotypes during Ipilimumab-Based Treatment By Long-Read Sequencing	Livius Penter, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1624 Cd70 Deficiency Impairs CD4+ and CD8+ T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas	Elisa Mandato, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1661 Ibrutinib and Venetoclax in Symptomatic, Treatment-Naïve Patients with Waldenström Macroglobulinemia	Jorge J. Castillo, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Saturday, December 9, 2023</b>		
1735 A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Jennifer L. Crombie, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1890 Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study	Jennifer R. Brown, MD, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1910 Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)	Kevin H. Lin, MD, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1914 A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)	Inhye E. Ahn, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1934 BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)	Debasmita Dutta, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1943 Transcriptomic Features Influencing Anti-Myeloma Drug Resistance in Human Multiple Myeloma Cell Lines	Filip Garbicz, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1946 Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia	Kris Richardson, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Saturday, December 9, 2023</b>		
1951 Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD <sup>+</sup> Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies	Giulia Giorgetti	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
1952 Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients	Maria Luisa Guerrero, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2026 Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenström's Macroglobulinemia	Yoshinobu Konishi, MD, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2087 Enhanced T Cell Function of PTPN2 Deleted CAR-T Cells Comes at a Cost: PTPN2 Knockout CAR-Ts Secrete More Cytokines and Demonstrate Increased Cytotoxicity, but Exhibit More Severe CRS and Icaans in a Non-Human Primate Model	Francesca Alvarez Calderon, MD, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2105 Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial	Grace Caroline Birch, PhD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2176 Post-Transplant T Cell Clonotype Diversity Is Associated with Survival in Patients with TP53-Mutated Acute Myeloid Leukemia	Nurefsan Sariipek, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2203 A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH) to Promote Well-Being: Randomized Controlled Feasibility and Preliminary Efficacy Trial	Hermioni L. Amonoo, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Saturday, December 9, 2023</b>		
2246 A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count	Stacey M. Frumm, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2347 A National Survey of Oncologists' Perspectives on the Ethical Implications of Artificial Intelligence in Cancer Care	Andrew Hantel, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2384 Establishing a Sociodemographic Data Banking Study in Patients with Hematologic Disorders – a Feasibility Assessment	Morohuntodun O. Oni	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center
2427 Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)	Miriam A. Osei, MD	5:30 – 7:30 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Sunday, December 10, 2023</b>		
2548 Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects	Michelle P. Aranha, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2640 Risks for Venous Thromboembolism with Immune Checkpoint Inhibitor Therapy	Jean M. Connors, MD, Brigham and Women's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2678 Dynamic Expression of Erg Controls Fetal-to-Adult Maturation of the Hematopoietic System	Mayuri Tanaka-Yano, PhD, Dana-Farber/Boston Children's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2699 In Vivo CRISPR Screening Platform for Studying Myeloid Inflammation and Clonal Dynamics	Peter Geon Kim, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2777 DHODH Inhibitor Therapy for the Treatment of T-ALL Spares the Developing Thymus	Amy Sexauer, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2785 The UBE2J2/UBE2K-MARCH5 Ubiquitination Machinery Regulates Apoptosis in Response to Venetoclax in Acute Myeloid Leukemia	Constanze Schneider, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2788 Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy	Jevon Cutler, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2802 Prediction of PP2A Holoenzymes Guided By the Structural Characterization of Methylation Independent PP2A Assembly	Franziska Wachter, MD, Dana-Farber/Boston Children's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2865 Organ Involvement in BPDCN Is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival	Shai Shimony, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Sunday, December 10, 2023</b>		
2875 Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL	Marlise R. Luskin, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
2924 Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation	Eric S. Winer, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3031 Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma	Austin I. Kim, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3160 TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms	Benjamin Rolles, MD, Brigham and Women's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3233 STAG2 Somatic Mutations Are Associated with Specific Dysplastic Megakaryocytic and Myeloid Cell Features in Myelodysplastic Syndrome	Waihay J. Wong, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3266 Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies	Roberta Santos Azevedo, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3270 Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients	Mariia Mikhaleva, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3293 Functional Characterization of Genes Residing in Chromosomal Regions with "High-Risk" Lesions in Multiple Myeloma	Phaik Ju Teoh, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Sunday, December 10, 2023</b>		
3298 Novel Protacs Demonstrate Dual Kinase Inhibition and Degradation of HCK and BTK, and Are Highly Active in MYD88 Mutated WM and ABC DLBCL Cells	Shirong Liu, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3300 Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTKCys481 Related BTK-Inhibitor Resistance	Shirong Liu, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3303 Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth	Maria Luisa Guerrero, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3311 Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy	Shuhui Deng, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3321 Integrated Molecular Landscape of Lesions in Cereblon and Its Pathway in Myeloma Patients: Insights into Mechanisms of Relapse from IMiD-Based Treatments	Lisa B. Leypoldt, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3382 Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma	Omar Nadeem, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3469 T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabletagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity	Shuntaro Ikegawa, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3499 Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma	Shonali Midha, MD, BS	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center



# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Sunday, December 10, 2023</b>		
3580 Integrative Single-Cell Tracking of Clonal Evolution, Leukemia Phenotypes and Donor Engraftment Following Allogeneic Stem Cell Transplant Using Mitochondrial DNA Mutations	Livius Penter, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3618 Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk	Stacey M. Frumm, MD, Brigham and Women's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3635 Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction	Mike P. Agius, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3638 Rapid-Kinetics Degron Benchmarking Reveals Off-Target Activities and Mixed Agonism-Antagonism of MYB Inhibitors	Maxim Pimkin, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3750 Patient and Parent-Reported Outcomes Post-Treatment with Shmir-Based Lentiviral Gene Therapy for Sickle Cell Disease	Lauren Jimenez-Kurlander, MD, Dana-Farber/Boston Children's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
3780 Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia	Shayna R. Sarosiek, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center



# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Monday, December 11, 2023</b>		
4143 Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma	Jean-Baptiste Alberge, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4174 Identifying Targeted Therapies for CBFA2T3-GLIS2 Acute Myeloid Leukemia	Fanny Gonzales, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4179 Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies	Binu Kandathilparambil Sasi, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4186 Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance	Torsten Steinbrunn, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4277 Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial	Andrew A. Lane, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4286 A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)	Matthew S. Davids, MD, MMSc	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4461 Odronektamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study	Jennifer L. Crombie, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4623 Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors	Aishath Naeem, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center

# Poster Presentations at ASH Annual Meeting

*Note: All times listed are Pacific Time. Schedule and locations subject to change by ASH.*

PRESENTATION	SPEAKER	TIME/LOCATION
<b>Monday, December 11, 2023</b>		
4652 Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)	Kevin H. Lin, MD, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4662 A SNAP23-Dependent SNARE Complex Mediates Free Light Chain Secretion in AL Amyloidosis and Multiple Myeloma and Its Blockade Triggers a Terminal Unfolded Protein Response and Massive Apoptosis	Emre Karayol, Brigham and Women's	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4671 A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)	Elizabeth K. O'Donnell, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4775 Understanding Patient Preferences for Intervention in Individuals with Precursor Multiple Myeloma: The Preference Study	Catherine R. Marinac, PhD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
4978 Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation	Mahasweta Gooptu, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center
5104 Feasibility of Utilizing a Virtual Health Assistant during Inpatient Reduced-Intensity Allogeneic Transplantation	Amar H. Kelkar, MD	6:00 – 8:00 p.m. Halls G-H San Diego Convention Center